Patent IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Olivier Dirat, et al.

Int'l Appln.

No.

PCT/GB03/03098

Int'l Date

Filed

17 July 2003 (17/07/2003)

Serial No.:

(To be assigned)

Case No.: T1587P

Filed

January 12, 2005

For

TETRAHYDROPYRAN DERIVATIVES AND THEIR

USE AS THERAPEUTIC AGENTS.

Commissioner for Patents

Commissioner for Patents Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT Jan 12, 2005

EXPRESS MAIL NO. EL9 89587828US

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS
BEING DEPOSITED WITH THE UNITED STATES POSTAL.

SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSES ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO

COMMISSIONER FOR PATENTS, PO. BOX 1450 ALEXANDRIA, VIRGINIA 223 3-1450.

MAILED BY LOTU ACT

DATE 00 12 2002

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the present application.

Copies of the references that are cited on the attached form PTO-1449 are enclosed herewith.

Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

Reg. No. 35,382

Attorney for Applicant

MERCK & CO., Inc.

P.O. Box 2000

Rahway, New Jersey 07065-0907

(732) 594-3904

Date: January 12, 2005

DT12 Rec'd PCT/PTO 1 2 JAN 2005

Sı	Substitute for form 1449A/PTO			Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE COMPLETE IF KNOWN			
INFORMATION DISC. SURE				Application Number	10/521338		
STATEMENT BY APPLICANT				Filing Date	January 1, 2005		
3	TATEMENT DI	AF	FLICANI	First Named Inventor	Olivier Dirat et al		
	(Group Art Unit			
	(use as many sheets	as n	ecessary)	Examiner Name			
Sheet	1	of	1	Attorney Docket Number	T1587P		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	
		US 2002/035132	Al	JOSE LUIS CASTRO PINEIRO	03/21/2002	
			-			
· · · ·						
	1					

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite	Foreign Patent Document Office Number		Kind	Name of Patentee or Applicant	Date of Publication of Cited Document	
	No.	Office	ivuilloci	Code (if known)	of Cited Document	MM-DD-YYYY	
			WO 00 56728		MERCK SHARP & DOHME	09/28/2000	
			WO 00 56727		MERCK SHARP & DOHME	09/28/2000	
			WO 03 22839		MERCK SHARP & DOHME	03/20/2003	

	The state of the s		
Examiner Signature		Date Considered	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.